At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 334 enrolled
Drug / intervention
Tislelizumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating Tislelizumab, Cisplatin, and 2 other interventions for Non-Small Cell Lung Cancer. Completed, enrolled 334 participants across 47 sites.
Detailed Summary
This study evaluated the efficacy and safety of tislelizumab in combination with platinum (cisplatin or carboplatin) and pemetrexed compared with platinum and pemetrexed alone as first-line treatment in participants with Stage IIIB or IV non-squamous non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartJul 2018
First PostedSep 2018
Primary CompletionJan 2020
Study CompletionApr 2023
TodayJul 2026
First PostedSep 10, 2018
Enrollment StartJul 23, 2018
Primary CompletionJan 23, 2020
Study CompletionApr 26, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.8 years ago
Interventions
Tislelizumabdrug
Administered intravenously
Cisplatindrug
Administered intravenously
Carboplatindrug
Administered intravenously
Pemetrexeddrug
Administered intravenously